Back grey_arrow_rt.gif
 
Archived NATAP Articles from October 2002
 
null.gif
 
 
  1. ADAP Waiting Lists in 12 States - (10/30/02)

  2.  
  3. CIRRHOSIS: advanced liver disease - (10/30/02)

  4.  
  5. Trends in hepatitis C and HIV infection among inmates entering prisons in California, 1994 versus 1999 - (10/30/02)

  6.  
  7. End Stage Liver Disease Leading Cause of Death in HCV/HIV Coinfected in France; 46% Had Cirrhosis; 37% had >200 Cd4s & <500 copies/ml viral load - (10/30/02)

  8.  
  9. 4th Lipodystrophy Workshop: metabolic abnormalities, HCV/HIV coinfection, fat loss, HCV/HIV coinfection - Michael Dube, MD, Indiana University School of Medicine, ACTG researcher - (10/30/02)

  10.  
  11. Abnormal lipids & GGT May Predict Poor Outcome in HCV/HIV Coinfection - (10/29/02)

  12.  
  13. ICAAC - HIV Entry Inhibitor: BMS-806 - (10/24/02)

  14.  
  15. ICAAC - Quality and Quantity in HIV Treatment: A Discussion of the Quad Therapy Symposium Presented at ICAAC - A Summary by Kimberly Smith MD, MPH For NATAP - (10/24/02)

  16.  
  17. ICAAC - Boosted PIs: differences emerging in efficacy, tolerability, lipids. - Graeme Moyle MD, MBBS, Associate Director of HIV Research, Chelsea and Westminster Hospital London, UK. - (10/24/02)

  18.  
  19. Adherence in HCV Therapy - (10/24/02)

  20.  
  21. IL-2 SILCAAT Clinical Study Discontinued - (10/24/02)

  22.  
  23. ICAAC - TMC-125, a new NNRTI for patients with NNRTI resistance: drug interactions with NNRTIs and protease inhibitors - (10/21/02)

  24.  
  25. Risk For Hepatitis C Transmission in Hospital/Clinic Setting: use of multidose medication vials- HCV transmission risk and management of acute HCV in hospital settings - (10/21/02)

  26.  
  27. ADAP HIV Drug Price Freeze by Bristol Myers Squibb - (10/21/02)

  28.  
  29. My New Liver - By Larry Kramer - (10/21/02)

  30.  
  31. Organ Transplants: We Must Have Presumed Consent - By Larry Kramer - (10/21/02)

  32.  
  33. Hep C Outbreak at Clinic The Associated Press - (10/17/02)

  34.  
  35. FDA Approves Pegasys Monotherapy Today - (10/17/02)

  36.  
  37. Hepatitis Cases May Be Linked to Needles at Clinic - By BARRY MEIER - (10/17/02)

  38.  
  39. Primary and Secondary Syphilis Among Men Who Have Sex with Men - New York City, 2001: HIV+ MSM leading epidemic - CDC Morbidity and Mortality Weekly Report - (10/15/02)

  40.  
  41. T-20, Fusion Inhibitor and its Availability - Press Release from Roche and Trimeris - (10/15/02)

  42.  
  43. ICAAC - Entry Inhibitors & New Test to Identify Co-receptor Use - (10/15/02)

  44.  
  45. ICAAC - Switch from d4T to Abacavir: changes in fat and mitochondria - (10/15/02)

  46.  
  47. ICAAC - Perspectives on hormonal, mitochondrial and metabolic changes - Reported by Mike Youle, MD, Royal Free Hospital, London - (10/15/02)

  48.  
  49. ICAAC - NRTI Sparing Regimens - (10/15/02)

  50.  
  51. Warning Issued on Reuse of Needles - (10/11/02)

  52.  
  53. ICAAC San Diego 2002: new therapy approaches; hormones and metabolicsReported by Mike Youle, MD, Royal Free Hospital, London - (10/9/02)

  54.  
  55. ICAAC - Lipid Analysis in Efavirenz & Nelfinavir Regimens - (10/8/02)

  56.  
  57. ICAAC - Switch Study in Children to Efavirenz from Protease Inhibitor - (10/8/02)

  58.  
  59. Effect of d4T and AZT on Leg Fat Loss - (10/7/02)

  60.  
  61. Barcelona Italian Heart Disease Study Withdrawn - (10/7/02)

  62.  
  63. Lipodystrophy, lactic acidosis/acidemia and mitochondrial toxicity issues - Written by Cecilia Shikuma, MD, University of Hawaii and ACTG lipodystrophy researcher
  64. - (10/7/02)
     
  65. ICCAC - Resistance to Atazanavir - (10/7/02)

  66.  
  67. ICCAC - HIV Healhcare Costs Driven by CD4 Count - (10/7/02)

  68.  
  69. ICCAC - Hepatitis C: Can You Replace the Liver Biopsy With Less Invasive Tests - (10/7/02)

  70.  
  71. ICCAC - Tenofovir in the Treatment of Individuals Co-Infected with HIV and Hepatitis B Abstract - (10/7/02)

  72.  
  73. ICCAC - PegIntron plus Ribavirin vs Interferon plus Rinavirin in HCV/HIV Coinfected Patients: preliminary week 48 results - (10/7/02)

  74.  
  75. ICCAC - Kaletra + Amprenavir & Boosted Ritonavir in PI Experiened Patients - (10/7/02)

  76.  
  77. ICCAC - Integrase Inhibitors Advancing: S-1360 & metabolic abormalities - (10/1/02)

  78.  
  79. ICCAC - T-20 and T-1249 - (10/1/02)

  80.